Great Point Partners’s Acumen Pharmaceuticals ABOS Stock Holding History

Great Point Partners’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,074,101	Closed	-$4.46M	–	35
2023 Q3	$4.46M	Buy	1,074,101 +22,834	+2%	+$141K	0.81%	35
2023 Q2	$5.06M	Hold	1,051,267	–	–	0.99%	30
2023 Q1	$4.27M	Sell	1,051,267 -65,314	-6%	-$341K	0.84%	30
2022 Q4	$6.03M	Sell	1,116,581 -83,419	-7%	-$561K	1.18%	30
2022 Q3	$12M	Sell	1,200,000 -315,000	-21%	-$1.81M	2.9%	13
2022 Q2	$7.12M	Buy	1,515,000 +586,718	+63%	+$2.2M	1.71%	24
2022 Q1	$3.63M	Buy	+928,282	New	+$5.05M	0.88%	25

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Great Point Partners's ABOS Position: Q4 2023 in Review

Great Point Partners sold out of Acumen Pharmaceuticals (ABOS) in Q4 2023, closing a stake of 1,074,101 shares — an estimated $4.46M sold.

Great Point Partners first reported a position in ABOS in Q1 2022 and held it in 7 quarters. The position peaked at $12M in Q3 2022. 67 funds tracked by Wall St. Rank hold ABOS as of Q4 2023.

Great Point Partners reported no remaining Acumen Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Great Point Partners sold 1,074,101 Acumen Pharmaceuticals shares in Q4 2023, an estimated $4.46M.
Great Point Partners first reported a position in Acumen Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Great Point Partners's Acumen Pharmaceuticals position peaked at $12M in Q3 2022.
67 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2023.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.